Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
5.53
Jul 28 • 3:59 PM ET Dollar change-0.53 Percentage change(-8.75%)
Aftermarket Close
5.47
Aftermarket • 5:00 PM ET Dollar change-0.06 Percentage change(-1.09%)
Jul 27, 7:52 PMChampions Oncology posts record FY 2026 revenue $59.4M with positive adjusted EBITDA while Q4 revenue $16.6M, EPS -$0.02 miss estimates
Index
-
Market Cap
76.79M
Enterprise Value
76.65M
Income
-1.11M
Sales
59.42M
Book/sh
0.28
Cash/sh
0.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
214
IPO
Jun 15, 1992
P/E
-
Forward P/E
-
PEG
-
P/S
1.29
P/B
19.50
P/C
15.77
P/FCF
-
EV/EBITDA
255.50
EV/Sales
1.29
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
1.17
LT Debt/Eq
0.76
Option/Short
Yes / Yes
EPS (ttm)
-0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
40.02% -
Sales past 3/5Y
3.33% 7.68%
EPS Y/Y TTM
-135.24%
Sales Y/Y TTM
4.36%
EPS Q/Q
64.02%
Sales Q/Q
11.98%
Insider Own
56.28%
Insider Trans
0.00%
Inst Own
17.86%
Inst Trans
91.47%
ROA
-3.76%
ROE
-28.89%
ROIC
-16.06%
Gross Margin
45.76%
Oper. Margin
-1.73%
Profit Margin
-1.87%
SMA20
-6.79%
SMA50
-8.24%
SMA200
-12.32%
Trades
Shs Outstand
13.89M
Shs Float
6.07M
52W High
8.74 -36.73%
52W Low
5.50 0.55%
Volatility
3.54% 5.43%
ATR (14)
0.37
RSI (14)
38.31
Beta
0.39
Rel Volume
3.62
Avg Volume
8.56K
Volume
30,941
Perf Week
-9.34%
Perf Month
-16.59%
Perf Quarter
-8.14%
Perf Half Y
-19.03%
Perf YTD
-19.97%
Perf Year
-12.22%
Perf 3Y
-14.73%
Perf 5Y
-47.73%
Perf 10Y
176.50%
Prev Close
6.06
Price
5.53
Change
-8.75%
Date Action Analyst Rating Change Price Target Change
Sep-12-24Upgrade Craig Hallum Hold → Buy $6
Nov-18-19Initiated The Benchmark Company Speculative Buy
Jul-27-26 04:00PM
Jul-20-26 04:30PM
Apr-09-26 01:40PM
Mar-30-26 10:55AM
Mar-18-26 09:00PM
08:30AM Loading…
Mar-13-26 08:30AM
Mar-12-26 04:01PM
Mar-05-26 04:00PM
Dec-16-25 12:00AM
Dec-15-25 04:00PM
Dec-08-25 04:00PM
Sep-16-25 03:01AM
Sep-15-25 04:50PM
03:55PM
Sep-10-25 04:30PM
03:11AM Loading…
Jul-24-25 03:11AM
Jul-23-25 04:00PM
Jul-21-25 08:30AM
Jul-18-25 08:30AM
Jul-08-25 08:30AM
Apr-28-25 09:45AM
Apr-24-25 08:00AM
Apr-21-25 04:20PM
Mar-11-25 03:55PM
Mar-06-25 04:00PM
Feb-18-25 09:00AM
Feb-14-25 03:47PM
Jan-09-25 08:30AM
Jan-08-25 08:00AM
Dec-11-24 04:00PM
04:30PM Loading…
Dec-05-24 04:30PM
Oct-16-24 10:55AM
Oct-09-24 07:00PM
03:05PM
Sep-12-24 08:03AM
Sep-11-24 04:00PM
Sep-09-24 04:00PM
Jul-18-24 09:53PM
04:00PM
Jul-11-24 04:05PM
Jun-04-24 09:00AM
Mar-19-24 08:28AM
Mar-12-24 04:30PM
Mar-07-24 09:00AM
Mar-06-24 04:35PM
Dec-14-23 08:22AM
Dec-12-23 09:54PM
04:00PM
Dec-04-23 04:30PM
Nov-02-23 08:30AM
Oct-17-23 08:30AM
Sep-13-23 04:00PM
Sep-11-23 04:00PM
Aug-22-23 08:30AM
Aug-01-23 08:45AM
Jul-24-23 04:00PM
Jul-20-23 04:00PM
Apr-17-23 08:30AM
Apr-05-23 09:50AM
Mar-15-23 03:50PM
Mar-13-23 08:30AM
Dec-16-22 08:48AM
Dec-13-22 04:00PM
Dec-09-22 04:30PM
Sep-08-22 04:00PM
Sep-06-22 04:00PM
Aug-15-22 08:08AM
Jul-23-22 09:57AM
Jul-21-22 04:00PM
Jul-14-22 04:00PM
Jun-13-22 06:30AM
May-31-22 08:30AM
May-03-22 08:30AM
May-02-22 01:16PM
Mar-15-22 04:45PM
Mar-11-22 08:30AM
Mar-07-22 01:10PM
Feb-15-22 08:30AM
Jan-20-22 08:30AM
Jan-04-22 08:30AM
05:07AM
Dec-13-21 04:20PM
Dec-06-21 09:20AM
Nov-05-21 08:24AM
Oct-20-21 10:25AM
Sep-13-21 04:00PM
Sep-06-21 03:00PM
07:09AM
Sep-02-21 04:30PM
Jul-26-21 08:30AM
Jul-22-21 08:00AM
Jul-14-21 08:30AM
Jul-08-21 03:06AM
Jun-15-21 09:00AM
Apr-29-21 03:31AM
Apr-16-21 12:00PM
Mar-16-21 10:52AM
Mar-15-21 02:13AM
Mar-11-21 04:00PM
02:30PM
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Executive ChairDr. Ronnie Morris M.D.
CEO & DirectorMr. Robert Brainin
Chief Financial OfficerMr. David Barry Miller M.B.A.
Chief Operating OfficerDr. Maria Mancini Ph.D.
Executive Vice President of GrowthDr. Marianna Zipeto Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ACKERMAN JOELDirectorOct 30 '25Option Exercise2.1094,405198,2501,056,539Nov 06 11:19 AM